Trim 10-15% of position; maintain core with hard stop at $248; re-enter on $275 breakout with volume or Q3 earnings confirmation

• Price tagged 269.39 with MACD off its 4.46 peak while making a higher high — textbook distribution
• Trailing P/E of 75x is a red flag; Q2 buybacks of $9 million versus historical billions signals management concerns
• Trim 10-15% (not 25-40%) to acknowledge technical distribution and harvest YTD gains while maintaining core exposure
• Hard stop at $248, below September swing low of 248.78 and lower Bollinger band at 250; exit remainder if violated
• Re-entry trigger at $275 on volume confirmation, or hold smaller core until Q3 earnings validates forward EPS trajectory
• ABBV profile: 2.61% dividend yield, 0.28 beta, 10.6x interest coverage, 2.1x net leverage — fortress balance sheet suited for rising yield regime
• Defensive yield names with secular demand drivers have outperformed in this regime; ABBV re-rates relative to speculative growth names getting hit
• Rinvoq 11th EU indication demonstrates franchise durability — label extensions matter for multiple expansion as Humira erosion is replaced by Skyrizi/Rinvoq
• Stay long ABBV rather than rotating to 'cleaner breakout' momentum names most exposed to multiple compression in current macro

→ vs aggressive: MACD divergence and trailing P/E are valid warnings, but the Rinvoq label expansion is not 'just a press release' — the 11th EU indication signals franchise durability, not contraction; calling it short-term thinking misses the multi-year compounding tailwind

→ vs neutral: HOLD without defined risk parameters (stop price, invalidation triggers) is not risk management — it's capitulation disguised as patience; a hard stop at $248 must be defined and honored, otherwise HOLD is just 'I don't want to make a decision'

Trim 15-20% of position now; maintain core AbbVie holding as defensive yield anchor; re-engage trimmed portion only after Q3 earnings confirm forward EPS trajectory AND price closes above $275 on volume

• MACD divergence confirmed: higher high at 269.39 with MACD off its 4.46 peak is a textbook distribution signature
• Q2 buybacks of $9 million versus multi-year aggressive repurchase history is a meaningful management signal
• Rinvoq pJIA approval is the eleventh European indication—a pattern supporting the multiple, not an incremental headline
• Iambic AI partnership represents strategic pipeline positioning at the intersection of AI discovery and large-pharma commercialization
• Beta of 0.28 is a feature in a regime where speculative growth names are being crushed; 97% no-cut macro supports defensive yield names
• AbbVie's 10.6x interest coverage and fortress balance sheet remain genuine defensive characteristics
• 75x trailing multiple acknowledged but positioned against the defensive yield justification
• 10.6x interest coverage cited as evidence of balance sheet strength
• Trefis flag on management disclosure practices should be on Q3 earnings call agenda

→ vs aggressive: The aggressive analyst's dismissal of the Rinvoq pediatric approval as 'incremental, not transformative' is lazy framing—eleven consecutive label expansions is a pattern supporting the multiple, not a headline to wave away

→ vs aggressive: The aggressive analyst is repeating the same mistake that destroyed capital in late 2023 and 2024 by concluding defensive yield names de-rate as ten-year yields rise—the conservative analyst is right that this thesis has been wrong for two years

→ vs aggressive: Selling a 0.28 beta compounder with 10.6x interest coverage to chase 'cleaner breakouts' in a 97% no-cut macro is reckless, as those momentum names carry the longest duration and most multiple compression risk

→ vs conservative: The conservative analyst's $248 hard stop sits below the recent swing low, meaning a normal volatility flush takes you out and then price rallies without you—it needs more room to breathe

→ vs conservative: The conservative analyst called $275 'structurally wrong' as a stop when the trader proposed it, but then proposed $275 as an entry trigger—that's a contradiction the analyst must own

→ vs conservative: A 10-15% trim is too small given the analyst acknowledges MACD divergence, upper-band rejection, and a 75x trailing multiple—if the technical warnings are real, position size should reflect that conviction

→ vs conservative: The conservative analyst completely ignored the competitive narrative around LLY at 49.6% revenue growth and MRK up 89% trailing—AbbVie can have a fortress balance sheet and still be the wrong holding relative to peers if the growth gap is structural